{"status":"ok","message-type":"work-list","message-version":"1.0.0","message":{"facets":{},"total-results":5166076,"items":[{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T07:12:35Z","timestamp":1648883555471},"reference-count":0,"publisher":"Case Journals","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CMR"],"DOI":"10.31525\/ct1-nct04249167","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T03:52:42Z","timestamp":1580442762000},"source":"Crossref","is-referenced-by-count":0,"title":["Cryoablation, Atezolizumab, and Nab-paclitaxel for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer"],"prefix":"10.31525","author":[{"name":"Case Medical Research","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16470","published-online":{"date-parts":[[2020,1,30]]},"container-title":["Case Medical Research"],"language":"en","deposited":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T03:52:44Z","timestamp":1580442764000},"score":62.086853,"resource":{"primary":{"URL":"https:\/\/my.casemedicalresearch.com\/api\/v2\/doi\/10.31525\/ct1-nct04249167"}},"issued":{"date-parts":[[2020,1,30]]},"references-count":0,"alternative-id":["10.31525\/ct1-nct04249167"],"URL":"https:\/\/doi.org\/10.31525\/ct1-nct04249167","ISSN":["2643-4652"],"issn-type":[{"value":"2643-4652","type":"print"}],"published":{"date-parts":[[2020,1,30]]}},{"indexed":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T06:57:19Z","timestamp":1709535439077},"reference-count":0,"publisher":"H1 Connect","content-domain":{"domain":[],"crossmark-restriction":false},"published-print":{"date-parts":[[2019,4,17]]},"DOI":"10.3410\/f.734257085.793559075","type":"dataset","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T09:50:14Z","timestamp":1555494614000},"source":"Crossref","is-referenced-by-count":0,"title":["Faculty Opinions recommendation of Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer."],"prefix":"10.3410","author":[{"given":"Ahmad","family":"Awada","sequence":"first","affiliation":[{"name":"Institut Jules Bordet, Universite Libre de Bruxelles, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4950","content-created":{"date-parts":[[2019,4,16]]},"container-title":["Faculty Opinions \u2013 Post-Publication Peer Review of the Biomedical Literature"],"deposited":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T21:40:36Z","timestamp":1587678036000},"score":61.885555,"resource":{"primary":{"URL":"https:\/\/facultyopinions.com\/prime\/734257085#eval793559075"}},"issued":{"date-parts":[[2019,4,16]]},"references-count":0,"URL":"https:\/\/doi.org\/10.3410\/f.734257085.793559075","relation":{"is-review-of":[{"id-type":"doi","id":"10.1056\/NEJMoa1809615","asserted-by":"subject"}]},"published":{"date-parts":[[2019,4,16]]}},{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T10:34:44Z","timestamp":1648722884169},"reference-count":0,"publisher":"Case Journals","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CMR"],"DOI":"10.31525\/ct1-nct04148911","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T03:50:12Z","timestamp":1572925812000},"source":"Crossref","is-referenced-by-count":0,"title":["A Study of Atezolizumab (Tecentriq) Plus Nab-Paclitaxel or Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer"],"prefix":"10.31525","author":[{"name":"Case Medical Research","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16470","published-online":{"date-parts":[[2019,11,4]]},"container-title":["Case Medical Research"],"language":"en","deposited":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T16:57:28Z","timestamp":1573059448000},"score":60.938675,"resource":{"primary":{"URL":"http:\/\/alpha.casemedicalresearch.com\/api\/v2\/doi\/10.31525\/ct1-nct04148911"}},"issued":{"date-parts":[[2019,11,4]]},"references-count":0,"alternative-id":["10.31525\/ct1-nct04148911"],"URL":"https:\/\/doi.org\/10.31525\/ct1-nct04148911","ISSN":["2643-4652"],"issn-type":[{"value":"2643-4652","type":"print"}],"published":{"date-parts":[[2019,11,4]]}},{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T04:12:03Z","timestamp":1773461523486,"version":"3.50.1"},"reference-count":10,"publisher":"Massachusetts Medical Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2019,3,7]]},"DOI":"10.1056\/nejmc1900150","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T22:07:05Z","timestamp":1551910025000},"page":"985-988","source":"Crossref","is-referenced-by-count":35,"title":["Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer"],"prefix":"10.1056","volume":"380","member":"150","reference":[{"key":"e_1_2_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615"},{"key":"e_1_2_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.243"},{"key":"e_1_2_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS15-P4-04-01"},{"key":"e_1_2_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24770"},{"key":"e_1_3_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006"},{"key":"e_1_3_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy103"},{"key":"e_1_4_3_2_2_2","article-title":"Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database.","author":"Chang E","year":"2018","unstructured":"Chang E, Mougalian SS, Adelson KB, Young MR, Yu JB. Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database. Breast Cancer Res Treat 2018 September 21 (Epub ahead of print).30242577","journal-title":"Breast Cancer Res Treat"},{"key":"e_1_4_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.04.011"},{"key":"e_1_5_3_2_2_2","doi-asserted-by":"crossref","unstructured":"Emens LA Loi S Rugo HS et al. IMpassion130: efficacy in immune biomarker subgroups from the global randomized double-blind placebo-controlled phase III study of atezolizumab + nab-paclitaxel in patients with treatment-na\u00efve locally advanced or metastatic triple-negative breast cancer (program no. GS1-04). Presented at the San Antonio Breast Cancer Symposium San Antonio TX December 4\u20138 2018. abstract.","DOI":"10.1158\/1538-7445.SABCS18-GS1-04"},{"key":"e_1_5_3_2_3_2","unstructured":"National Comprehensive Care Network. Clinical practice guidelines in oncology: breast cancer version 3. NCCN 2018 (https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf)."}],"container-title":["New England Journal of Medicine"],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMc1900150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:42:34Z","timestamp":1711500154000},"score":60.583126,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMc1900150"}},"issued":{"date-parts":[[2019,3,7]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,3,7]]}},"alternative-id":["10.1056\/NEJMc1900150"],"URL":"https:\/\/doi.org\/10.1056\/nejmc1900150","ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"published":{"date-parts":[[2019,3,7]]}},{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T04:21:06Z","timestamp":1782015666323,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s40265-020-01295-y","type":"journal-article","created":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T09:02:17Z","timestamp":1585990937000},"page":"601-607","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer"],"prefix":"10.1007","volume":"80","author":[{"given":"Connie","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahiya Y.","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,4]]},"reference":[{"key":"1295_CR1","unstructured":"GLOBOCAN. New global cancer data: GLOBOCAN 2018. 2018. https:\/\/www.uicc.org. Accessed 16 Mar 2020."},{"issue":"1","key":"1295_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/cncr.28914","volume":"121","author":"VG Abramson","year":"2015","unstructured":"Abramson VG, Lehmann BD, Ballinger TJ, et al. Subtyping of triple-negative breast cancer: implications for therapy. Cancer. 2015;121(1):8\u201316.","journal-title":"Cancer"},{"issue":"2","key":"1295_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10549-016-4059-6","volume":"161","author":"XX Li","year":"2017","unstructured":"Li XX, Yang J, Peng LM, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 2017;161(2):279\u201387.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1295_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/ajco.12748","volume":"14","author":"P Khosravi-Shahi","year":"2017","unstructured":"Khosravi-Shahi P, Cabez\u00f3n-Guti\u00e9rrez L, Custodio-Cabello S. Metastatic triple negative breast cancer: optimizing treatment options, new and emerging targeted therapies. Asia Pac J Clin Oncol. 2017;14(1):32\u20139.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"22","key":"1295_CR5","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108\u201321.","journal-title":"N Engl J Med"},{"key":"1295_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00031","author":"C Neophytou","year":"2018","unstructured":"Neophytou C, Boutsikos P, Papageorgis P. Molecular mechanisms and emerging therapeutic targets of triple-negative breast cancer metastasis. Front Oncol. 2018. https:\/\/doi.org\/10.3389\/fonc.2018.00031.","journal-title":"Front Oncol"},{"key":"1295_CR7","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer v 3.2020. 2020. https:\/\/www.nccn.org. Accessed 16 Mar 2020."},{"issue":"8","key":"1295_CR8","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","volume":"29","author":"European Society for Medical Oncology","year":"2018","unstructured":"European Society for Medical Oncology. 4th ESO\u2013ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol. 2018;29(8):1634\u201357.","journal-title":"Ann Oncol"},{"key":"1295_CR9","unstructured":"National Institute for Health and Care Excellence. NICE pathways: managing advanced breast cancer. 2019. https:\/\/pathways.nice.org.uk. Accessed 16 Mar 2020."},{"key":"1295_CR10","unstructured":"The American Cancer Society. Treatment of triple-negative breast cancer. 2019. https:\/\/www.cancer.org. Accessed 16 Mar 2020."},{"issue":"3","key":"1295_CR11","first-page":"227","volume":"19","author":"FS Cyprian","year":"2019","unstructured":"Cyprian FS, Akhtar S, Gatalica Z, et al. Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: a new clinical paradigm in the treatment of triple-negative breast cancer. Bosn J Basic Med Sci. 2019;19(3):227\u201333.","journal-title":"Bosn J Basic Med Sci"},{"issue":"4","key":"1295_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","volume":"2","author":"EA Mittendorf","year":"2014","unstructured":"Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4):361\u201370.","journal-title":"Cancer Immunol Res"},{"issue":"274","key":"1295_CR13","first-page":"1","volume":"7","author":"L Molinero","year":"2019","unstructured":"Molinero L, Li YJ, Chang CW, et al. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. J Immunother Cancer. 2019;7(274):1\u20139.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1295_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/0284186X.2017.1400180","volume":"57","author":"ES Stovgaard","year":"2018","unstructured":"Stovgaard ES, Nielsen D, Hogdall E, et al. Triple negative breast cancer\u2014prognostic role of immune-related factors: a systematic review. Acta Oncol. 2018;57(1):74\u201382.","journal-title":"Acta Oncol"},{"issue":"1","key":"1295_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12967-018-1514-7","volume":"16","author":"ZH Li","year":"2018","unstructured":"Li ZH, Qiu YR, Lu WQ, et al. Immunotherapeutic interventions of triple negative breast cancer. J Transl Med. 2018;16(1):147.","journal-title":"J Transl Med"},{"key":"1295_CR16","unstructured":"Genentech. TECENTRIQ\u00ae (atezolizumab) injection, for intravenous use: US prescribing information. 2019. https:\/\/www.fda.gov. Accessed 16 Mar 2020."},{"key":"1295_CR17","unstructured":"European Medicines Agency. Tecentriq 840 mg concentrate for solution for infusion: EU summary of product characteristics. 2019. https:\/\/www.ema.europa.eu. Accessed 16 Mar 2020."},{"key":"1295_CR18","unstructured":"Pharmaceuticals and Medical Devices Agency. Tecentriq IV 840\u00a0mg\/Tecentriq IV 1200\u00a0mg: prescribing information. 2019. https:\/\/www.pmda.go.jp. Accessed 16 Mar 2020."},{"key":"1295_CR19","unstructured":"Celgene Corporation. ABRAXANE\u00ae (paclitaxel protein-bound particles for injectable suspension) for injectable suspension (albumin-bound): US prescribing information. 2019. https:\/\/www.fda.gov. Accessed 16 Mar 2020."},{"issue":"1","key":"1295_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44\u201359.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1295_CR21","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/jjco\/hyz135","volume":"49","author":"H Iwata","year":"2019","unstructured":"Iwata H, Inoue K, Kaneko K, et al. Subgroup analysis of Japanese patients in a phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130). Jpn J Clin Oncol. 2019;49(12):1083\u201391.","journal-title":"Jpn J Clin Oncol"},{"issue":"Supp 9","key":"1295_CR22","doi-asserted-by":"publisher","first-page":"ix13","DOI":"10.1093\/annonc\/mdz418","volume":"30","author":"H Iwata","year":"2019","unstructured":"Iwata H, Im SA, Sohn J, et al. Subgroup analysis of IMpassion130: atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries [abstract no. 370]. Ann Oncol. 2019;30(Supp 9):ix13\u20134.","journal-title":"Ann Oncol."},{"issue":"Suppl 15","key":"1295_CR23","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1200\/JCO.2019.37.15_suppl.1067","volume":"37","author":"S Adams","year":"2019","unstructured":"Adams S, Dieras V, Barrios CH, et al. Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nabpaclitaxel (nP) in metastatic triple-negative breast cancer (mTNBC) [abstract]. J Clin Oncol. 2019;37(Suppl 15):1067.","journal-title":"J Clin Oncol"},{"key":"1295_CR24","doi-asserted-by":"crossref","unstructured":"Emens LA, Loi S, Rugo HS, et al. IMpassion130: efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naive, locally advanced or metastatic triple-negative breast cancer [abstract no. GS1-04 and presentation]. Cancer Res. 2018;79(Suppl 4):GS1-04-GS1-04.","DOI":"10.1158\/1538-7445.SABCS18-GS1-04"},{"issue":"5","key":"1295_CR25","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3747\/co.25.4235","volume":"25","author":"G Myers","year":"2018","unstructured":"Myers G. Immune-related adverse events of immune checkpoint inhibitors: a brief review. Curr Oncol. 2018;25(5):342\u20137.","journal-title":"Curr Oncol"},{"issue":"67","key":"1295_CR26","doi-asserted-by":"publisher","first-page":"111931","DOI":"10.18632\/oncotarget.22953","volume":"8","author":"MP Kuczma","year":"2017","unstructured":"Kuczma MP, Ding ZC, Li T, et al. The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumorreactive T cells. Oncotarget. 2017;8(67):111931\u201342.","journal-title":"Oncotarget"},{"issue":"4","key":"1295_CR27","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.ccell.2018.03.015","volume":"33","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Helmink BA, Spencer CN, et al. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell. 2018;33(4):570\u201380.","journal-title":"Cancer Cell"},{"key":"1295_CR28","unstructured":"National Institute for Health and Care Excellence. Atezolizumab with nab-paclitaxel for treating PD-L1-positive, triple-negative, advanced breast cancer: committee discussion. 2019. https:\/\/www.nice.org.uk. Accessed 16 Mar 2020."},{"key":"1295_CR29","unstructured":"National Institute for Health and Care Excellence. Single technology appraisal: atezolizumab with nab-paclitaxel for treating PD L1-positive, triple-negative, advanced breast cancer [ID1522] committee papers. 2019. https:\/\/www.nice.org.uk. Accessed 16 Mar 2020."},{"key":"1295_CR30","doi-asserted-by":"publisher","unstructured":"Weng XH, Huang XT, Li HC, et al. First-line treatment with atezolizumab plus nab-paclitaxel for advanced triple-negative breast cancer: a cost-effectiveness analysis. Am J Clin Oncol. 2020. https:\/\/doi.org\/10.1097\/COC.0000000000000671. Accessed 16 Mar 2020.","DOI":"10.1097\/COC.0000000000000671"},{"issue":"3","key":"1295_CR31","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/jamaoncol.2018.5152","volume":"5","author":"S Adams","year":"2019","unstructured":"Adams S, Diamond JR, Hamilton E, et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial. JAMA Oncol. 2019;5(3):334\u201342.","journal-title":"JAMA Oncol"}],"container-title":["Drugs"],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01295-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-020-01295-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01295-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T23:14:28Z","timestamp":1617491668000},"score":58.893036,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-020-01295-y"}},"issued":{"date-parts":[[2020,4]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1295"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01295-y","ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"4 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Connie Kang and Yahiya Y. Syed are salaried employees of Adis International Ltd\/Springer Nature, are responsible for the article content and declare no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}],"items-per-page":5,"query":{"start-index":0,"search-terms":null}}}